Glycerol Phenylbutyrate 相關新聞

← 返回新聞總覽


Glycerol Phenylbutyrate 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Glycerol Phenylbutyrate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine...
  • 證據等級:L5
  • 預測適應症(20 個):
    • urea cycle disorder(98.7%)
    • argininosuccinic aciduria(98.2%)
    • carbamoyl phosphate synthetase I deficiency disease(97.9%)
    • acute neonatal citrullinemia type I(97.2%)
    • adult-onset citrullinemia type I(97.2%)
    • citrullinemia, type II, adult-onset(97.1%)
    • 3-methylcrotonyl-CoA carboxylase 1 deficiency(97.1%)
    • hyperinsulinism-hyperammonemia syndrome(96.8%)
    • hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency(96.6%)
    • hyperargininemia(95.0%)
    • citrullinemia(94.3%)
    • citrin deficiency(93.5%)
    • neonatal intrahepatic cholestasis due to citrin deficiency(92.7%)
    • benign neoplasm of adrenal gland(90.8%)
    • hyperammonemia due to N-acetylglutamate synthase deficiency(89.0%)
    • familial apolipoprotein C-II deficiency(86.3%)
    • polycystic kidney disease 3 with or without polycystic liver disease(83.1%)
    • acute intermittent porphyria(81.3%)
    • renal-hepatic-pancreatic dysplasia(79.6%)
    • autosomal ichthyosis syndrome with fatal disease course(79.5%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.